Search Clinical Trials in the European Union

6-12 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
161-180 of 397 trials

Non-Alcoholic Steatohepatitis: Namodenoson Study

We are testing a new oral medication, namodenoson, for individuals with Non-Alcoholic Steatohepatitis (NASH). The study aims to see if it improves liver health and to evaluate its safety.

Non-Alcoholic Steatohepatitis (NASH)6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementHepatologyInternal Medicine

High-Risk Medulloblastoma: New Treatment Approaches

We are exploring whether new radiotherapy and chemotherapy methods improve outcomes for children and adults with high-risk medulloblastoma. The study also looks at the long-term effects of these treatments on patients' health and quality of life.

Medulloblastoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncologyPediatrics

Systemic Lupus Erythematosus: Obexelimab Study

We are studying a new medication, Obexelimab, for patients with systemic lupus erythematosus to see if it can lower disease activity and reduce fatigue. This trial compares its effects to a placebo treatment.

Systemic Lupus Erythematosus6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Parkinson's Disease: New Approaches to Levodopa Resistance

We are studying whether the medication apomorphine or the antibiotic rifaximin can help people with Parkinson's disease who struggle with levodopa treatment. This trial aims to improve their symptoms and overall treatment response.

Parkinson's Disease6-12 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementInternal MedicineNeurology

Denosumab: Impact on Muscle Strength and Insulin Sensitivity

We are studying whether denosumab can improve muscle strength and insulin sensitivity in participants. This trial compares its effects to a placebo to understand its potential benefits.

Diabetes MellitusPostmenopausal Osteoporosis6-12 monthsMonitoring phase (IV)Standard MedicinesEndocrinologyHepatologyInternal Medicine

Membranous Nephropathy: Personalized Rituximab Treatment Study

We are exploring whether an AI-driven personalized treatment plan for membranous nephropathy is more effective than standard rituximab treatment. This study aims to improve patient outcomes and remission rates.

Acute GlomerulonephritisMembranous Nephropathy6-12 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesNephrology

GEN1047 for Solid Tumors - First in Human Trial

We are testing a new treatment called GEN1047 for people with malignant solid tumors. The study aims to find the safest dose and evaluate how well it works against cancer.

Malignant Solid Tumors6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Cirrhosis Treatment: Efinopegdutide Study

We are testing efinopegdutide in adults with compensated cirrhosis caused by metabolic dysfunction. The study aims to see if it can reduce liver fat and improve liver health compared to a placebo.

Non-alcoholic Steatohepatitis6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesEndocrinologyHepatology

Cognitive Impairment in Parkinson's: Donepezil Study

We are studying whether donepezil can improve cognitive function in people with mild cognitive impairment due to Parkinson's disease. The trial will also evaluate its effects on mental health and quality of life.

Parkinson's Disease6-12 monthsEfficacy phase (II)6-10 visitsStandard MedicinesNeurology

Glioblastoma Treatment: Olaptesed Pegol with Radiation

We are studying the safety and effectiveness of olaptesed pegol combined with radiation therapy for patients with newly diagnosed glioblastoma and unmethylated MGMT promoter. This trial also explores how different doses may impact treatment outcomes.

Glioblastoma6-12 monthsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Diffuse Large B-Cell Lymphoma: Epcoritamab Plus Lenalidomide

We are studying whether a new combination of epcoritamab and lenalidomide can improve survival rates for adults with relapsed or refractory diffuse large B-cell lymphoma compared to standard treatments.

Relapsed or Refractory Diffuse Large B-Cell Lymphoma6-12 monthsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Advanced Prostate Cancer: Debio 4228 Study

We are testing a new medication, Debio 4228, to see if it effectively lowers hormone levels in men with advanced prostate cancer. The study will also look at how well the medication is tolerated and its safety profile.

Advanced Prostate Cancer6-12 monthsEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Obsessive-Compulsive Disorder: Pramipexole Treatment Study

We are investigating whether pramipexole can improve treatment outcomes for individuals with resistant OCD. The study will also assess the safety of this medication and its effects on brain function.

Obsessive-Compulsive Disorder (OCD)6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesPsychiatry

Senicapoc for Progressive Fibrotic Interstitial Lung Disease

We are studying whether Senicapoc can help slow the progression of lung disease in patients with progressive fibrotic ILD. This trial compares its effects to a placebo alongside standard care.

Interstitial Pulmonary Fibrosis6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPulmonology

Myotonic Dystrophy: Mexiletine PR Study

We are investigating whether once daily mexiletine can help reduce muscle stiffness in patients with myotonic dystrophy types 1 and 2. The study will also look at its safety and how it affects daily activities.

Myotonic Dystrophy6-12 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Solid Tumors: NECVAX-NEO1 with PD-1/PD-L1 Therapy

We are studying a new treatment, NECVAX-NEO1, for patients with solid tumors already on PD-1 or PD-L1 therapy. The trial aims to assess its safety and how well it may work in combination with existing treatments.

Advanced Solid Tumors6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Celiac Disease: Amlitelimab Treatment Study

We are investigating whether amlitelimab can help adults with non-responsive celiac disease improve their symptoms and intestinal health while on a gluten-free diet. The study also examines the safety of this new treatment.

Coeliac Disease6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Parkinson’s Disease and Multiple System Atrophy: Exidavnemab Study

We are testing the safety and tolerability of a new treatment called exidavnemab in patients with Parkinson’s disease and Multiple System Atrophy. This study will help us understand how well different doses are accepted by patients.

Parkinson's DiseaseMultiple System Atrophy6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteNeurology

Dental Implant Surgery: Antibiotics Study

We are investigating whether taking antibiotics helps patients recover better after dental implant surgery with bone regeneration and sinus elevation. This study compares the effects of antibiotics to a placebo on patient outcomes.

Implant Surgery with Guided Bone Regeneration6-12 monthsMonitoring phase (IV)6-10 visitsInvestigational MedicinesGynecology and ObstetricsInfectious DiseasesOrthopedics and TraumatologyOtolaryngology

Rheumatoid Arthritis: Baricitinib and Anti-TNF Combination Study

We are investigating whether combining baricitinib with anti-TNF therapy helps patients with rheumatoid arthritis who haven't responded to other treatments. The study will also look at safety and how well patients can reduce their steroid use.

Rheumatoid Arthritis6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesRheumatology